Lv22
113 积分 2025-02-06 加入
Clinician’s Guide to the 2024 VA/DoD Clinical Practice Guideline for the Rehabilitation of Individuals With Lower Limb Amputation
9小时前
求助中
Lymph Node Pathologic Grading Strategy: under the backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma – a retrospective cohort study among Asian patients
6天前
已完结
EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy
12天前
已完结
Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial
14天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
19天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
19天前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
20天前
已完结
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
21天前
已完结
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial
28天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
1个月前
已完结
皖公网安备34019202002308
